Teva Shares Rally on Opioid Settlement, but Analysts Have Doubts

Tentative $23 billion deal announced on Monday could be boost for financially troubled Israeli drug maker. But deal remains short on details, and not all the plaintiffs may sign on

Yoram Gabison
Reuters
Send in e-mailSend in e-mail
The logo for Teva appears above a trading post on the floor of the New York Stock Exchange, October 21, 2019.
The logo for Teva appears above a trading post on the floor of the New York Stock Exchange, October 21, 2019. Credit: Richard Drew,AP

Comments